Arcutis Biotherapeutics Inc Stock News

The average of price targets set by Wall Street analysts indicates a potential upside of 99.9% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is question

Investors with any experience in the world of penny stocks know that risk is real. That risk is higher as the price of shares goes lower.

Investigational roflumilast cream 0.15% showed continued improvements in the signs and symptoms of AD, including itch, through 56 weeks of treatment 66.2% of participants treated with once-daily roflu

WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in

Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Canopy Growth Corporation (CGC) have performed compared to their sector so far this year.

The consensus price target hints at a 101.1% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Latha Vairavan - Vice President, Finance and Head of Investor Relations Frank

First quarter net product revenues for ZORYVE® franchise of $21.6M, with $15M for ZORYVE (roflumilast) cream 0.3%, and $6.5M for ZORYVE (roflumilast) topical foam, 0.3%; sales growth of 675% vs. Q1 '

Japan's Mitsubishi UFJ also ranks highly within IBD's Banks-Money Center industry group.

The 5% buy zone past the breakout point in Bitfarms goes up to 3.74.

Heritage shares have cut through that price resistance like a hot knife through butter.

The proper buy zone from Aris Mining's breakout point goes up to 5% past 3.54, or 3.72.

Arcos Dorados has broken out past resistance at 8 after forming two bases over the past 12 months. The post Cheap Stocks To Buy: Should You Watch These 5 Growth Stocks?

Watch to see if Teekay stock can catapult past the prior entry of 7.67, or form yet another base.

Eight of nine experts expressed feeling “extremely confident” about prescribing ZORYVE foam to patients of diverse skin and hair types, including individuals with previous hair treatments, based o